Fibrosis is a major driver of chronic disease and organ failure across multiple tissues, yet effective therapies remain extremely limited. While prior fibrosis meetings have focused largely on skin, liver, and lung, significant knowledge gaps remain in other clinically important organs, including kidney, bone marrow, intestine, heart, and in the context of cancer. This meeting is designed to address these gaps by reframing fibrosis as a multi-organ disease with both shared and organ-specific mechanisms that must be understood to advance human health. The primary goal of the meeting is to bring together basic, translational, clinical, and industry researchers to identify conserved pathogenic pathways, define critical differences across tissues, and accelerate the development of effective antifibrotic therapies. The program emphasizes cross-organ comparisons, emerging therapeutic modalities, and the growing need for precision and combination treatment strategies.

This meeting is timely as fibrosis research is at an inflection point: new single-cell and systems-level technologies are rapidly expanding biological insight, while intense industry investment reflects both unmet clinical need and emerging therapeutic opportunity. However, progress remains uneven across organs, highlighting the need for integrated, interdisciplinary discussion.  This meeting is designed to bring together academic investigators, clinician-scientists, trainees, and biotechnology and pharmaceutical researchers working across fibrosis, chronic disease, and translational medicine. By uniting communities that are often siloed by organ system, this conference is distinct from existing meetings and directly addresses a critical barrier to progress in the field. Participants will leave with a clearer understanding of the mechanisms driving fibrosis across organs, the state of antifibrotic drug development, and key open questions shaping future research and clinical translation. The meeting is expected to catalyze new collaborations, inform therapeutic strategies, and help define next-generation approaches to treating fibrotic disease.  

This conference will be held jointly with Metabolic Approaches to Chronic Liver Disease, creating a unique interdisciplinary forum that connects fibrosis biology with metabolic dysfunction. The joint format will foster cross-disciplinary dialogue, expand perspectives beyond traditional boundaries, and generate new insights into shared disease mechanisms and therapeutic opportunities that would not emerge in a single-focus meeting.